A Phase 2 trial investigating an orally administered MEK kinase inhibitor (Selumetinib) for patients with NF1 GIST is underway at the NIH in Bethesda, Maryland.  The full title of the trial is:

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

The trial can be viewed at clinicaltrials.gov by clicking on the following link

https://clinicaltrials.gov/ct2/show/NCT03109301?term=NF-1&cond=GIST&rank=1